Drug discovery in academia

American Journal of Physiology - Cell Physiology

Volumn 286, Issue 3 55-3, 2004, Pages

  Verkman, A S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cystic fibrosis transmembrane conductance regulator; Drug development; Fluorescence; High throughput screening; Pharmacology

Indexed keywords

4 THIAZOLIDINONE DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; CHLORIDE CHANNEL; CHLORIDE CHANNEL STIMULATING AGENT; CYCLIC GMP; FLAVONE DERIVATIVE; GREEN FLUORESCENT PROTEIN; NEW DRUG; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITOR; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

CYSTIC FIBROSIS; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG DISCOVERY; DRUG EFFICACY; DRUG MARKETING; DRUG POTENCY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; KNOCKOUT GENE; NONHUMAN; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RARE DISEASE; REVIEW; UNIVERSITY HOSPITAL;

ANIMALIA;

EID: 1442349808     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00397.2003     Document Type: Review

References (45)

1. Akamatsu M. Current state and perspectives of 3D-QSAR. Curr Top Med Chem 2: 1381-1394, 2002.
2. Barreca ML, Gitto R, Quartarone S, De Luca L, De Sarro G, and Chimirri A. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists. J Chem Inf Comput Sci 43: 651-655, 2003.
3. Battersby BJ and Trau M. Novel miniaturized systems in high-throughput screening. Trends Biotechnol 20: 167-173, 2002.
4. Bleicher KH, Bohm HJ, Muller K, and Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2: 369-378, 2003.
5. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, and Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358: 761-764, 1992.
6. DiMasi JA, Hansen RW, and Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185, 2003.
7. Dove A. Screening for content - the evolution of high throughput. Nat Biotechnol 21: 859-864, 2003.
8. Drews J. Strategic trends in the drug industry. Drug Disc Today 8: 411-420, 2003.
9. Engel LW and Straus SE. Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov 1: 229-237, 2002.
10. Galietta LV, Haggie PM, and Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 499: 220-224, 2001.
11. Galietta LV, Jayaraman S, and Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 281: C1734-C1742, 2001.
12. Galietta LV, Springsteel M, Eda M, Niedzinski EJ, By K, Haddadin M, Kurth MJ, Nantz MH, and Verkman AS. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 276: 19723-19728, 2001.
13. Geysen HM, Schoenen F, Wagner D, and Wagner R. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nat Rev Drug Discov 2: 222-230, 2003.
14. Green DV. Virtual screening of virtual libraries. Prog Med Chem 41: 61-97, 2003.
15. Hertzberg RP and Pope AJ. High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol 4: 445-451, 2000.
16. Jayaraman S, Haggie P, Wachter R, Remington SJ, and Verkman AS. Mechanism and cellular applications of a green fluorescent protein-based halide sensor. J Biol Chem 275: 6047-6050, 2000.
17. Jayaraman S, Joo NS, Reitz B, Wine JJ, and Verkman AS. Submucosal gland secretions in airways from cystic fibrosis patients have normal salt and pH but elevated viscosity. Proc Natl Acad Sci USA 98: 8119-8123, 2001.
18. Jayaraman S, Teitler L, Skalski B, and Verkman AS. Long-wavelength iodide-sensitive fluorescent indicators for measurement of functional CFTR expression in cells. Am J Physiol Cell Physiol 277: C1008-C1018, 1999.
19. Kenakin T. Predicting therapeutic value in the lead optimization phase of drug discovery. Nat Rev Drug Discov 2: 429-438, 2003.
20. Knowles J and Gromo G. A guide to drug discovery: target selection in drug discovery. Nat Rev Drug Discov 2: 63-69, 2003.
21. Krejsa CM, Horvath D, Rogalski SL, Penzotti JE, Mao B, Barbosa F, and Migeon JC. Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Devel 6: 470-480, 2003.
22. Langer T and Krovat EM. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr Opin Drug Discov Devel 6: 370-376, 2003.
23. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, and Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3: 1125-1154, 2003.
24. Lipsky MS and Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract 14: 362-367, 2001.
25. Livingstone DJ. Theoretical property predictions. Curr Top Med Chem 3: 1171-1192, 2003.
26. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, and Verkman AS. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera-toxin induced intestinal fluid secretion. J Clin Invest 110: 1651-1658, 2002.
27. Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran N, Galietta LV, and Verkman AS. High-affinity activators of CFTR chloride conductance identified by high-throughput screening. J Biol Chem 277: 37235-37241, 2002.
28. Mansoura M, Biwersi J, Ashlock M, and Verkman AS. Fluorescent chloride indicators to assess the efficacy of CFTR cDNA delivery. Hum Gene Ther 10: 861-875, 1999.
29. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2: 695-702, 2003.
30. Roberts SA. Drug metabolism and pharmacokinetics in drug discovery. Curr Opin Drug Discov Devel 6: 66-80, 2003.
31. Schleifer KJ and Tot E. Pharmacophore modelling of structurally unusual diltiazem mimics at L-type calcium channels. J Comput Aided Mol Des 14: 427-433, 2000.
32. Smith PA, Sorich MJ, McKinnon RA, and Miners JO. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyl-transferase 1A4 substrate selectivity. J Med Chem 46: 1617-1626, 2003.
33. Solon EG, Balani SK, and Lee FW. Whole-body autoradiography in drug discovery. Curr Drug Metab 3: 451-462, 2002.
34. Springsteel M, Galietta LJ, Ma T, By K, Berger Go Yang H, Dicus CW, Choung W, Quan C, Shelat AA, Guy RK, Verkman AS, Kurth MJ, and Nantz MH. Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model of flavone-CFTR binding. Bioorg Med Chem 11: 4113-4120, 2003.
35. Thiagarajah J, Broadbent T, Hsieh E, and Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology. In press.
36. Thiagarajah JR, Song Y, Haggie PM, and Verkman AS. CFTR inhibition in airway submucosal glands reduces fluid secreted fluid volume and pH and increases viscosity without altering salt content (Abstract). Pediatr Pulmonol Suppl 25: 213, 2003.
37. Thiagarajah JR and Verkman AS. CFTR pharmacology and role in secretory diarrheas. Curr Opin Pharm. In press.
38. Tong W, Welsh WJ, Shi L, Fang H, and Perkins R. Structure-activity relationship approaches and applications. Environ Toxicol Chem 22: 1680-1695, 2003.
39. Tropsha A and Zheng W. Rational principles of compound selection for combinatorial library design. Comb Chem High Throughput Screen 5: 111-123, 2002.
40. Van Drie JH. Pharmacophore discovery-lessons learned. Curr Pharm Des 9: 1649-1664, 2003.
41. Verkman AS, Pedemonte N, Du K, Lukacs G, Shelat A, Guy K, and Galietta LV. Small-molecule activators (potentiators and correctors) of ΔF508-CFTR identified by high-throughput screening (Abstract). Pediatr Pulmonol Suppl 25: 190, 2003.
42. Wachter RM, Yarbough D, Kallio K, and Remington SJ. Crystallographic and energetic analysis of binding of selected anions to the yellow variants of green fluorescent protein. J Mol Biol 301: 157-171, 2001.
43. Watt AP, Mortishire-Smith RJ, Gerhard U, and Thomas SR. Metabolite identification in drug discovery. Curr Opin Drug Discov Devel 6: 57-65, 2003.
44. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, Galietta LV, and Verkman AS. Nanomolar affinity small-molecule correctors of defective ΔF508-CFTR chloride channel gating. J Biol Chem 278: 35079-35085, 2003.
45. Zhang JH, Chung TD, and Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73, 1999.